Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models

Objectives To determine the value of conventional DWI, continuous-time random walk (CTRW), fractional order calculus (FROC), and stretched exponential model (SEM) in discriminating human epidermal growth factor receptor 2 (HER2) status of breast cancer (BC). Methods This prospective study included 158 women who underwent DWI, CTRW, FROC, and SEM and were pathologically categorized into the HER2-zero-expressing group ( n = 10), HER2-low-expressing group ( n = 86), and HER2-overexpressing group ( n = 62). Nine diffusion parameters, namely ADC, α CTRW , β CTRW , D CTRW , β FROC , D FROC , μ FROC , α SEM , and DDC SEM of the primary tumor, were derived from four diffusion models. These diffusion metrics and clinicopathologic features were compared between groups. Logistic regression was used to determine the optimal diffusion metrics and clinicopathologic variables for classifying the HER2-expressing statuses. Receiver operating characteristic (ROC) curves were used to evaluate their discriminative ability. Results The estrogen receptor (ER) status, progesterone receptor (PR) status, and tumor size differed between HER2-low-expressing and HER2-overexpressing groups ( p < 0.001 to p = 0.009). The α CTRW , D CTRW , β FROC , D FROC , μ FROC , α SEM , and DDC SEM were significantly lower in HER2-low-expressing BCs than those in HER2-overexpressing BCs ( p < 0.001 to p = 0.01). Further multivariable logistic regression analysis showed that the α CTRW was the single best discriminative metric, with an area under the curve (AUC) being higher than that of ADC (0.802 vs. 0.610, p < 0.05); the addition of ER status, PR status, and tumor size to the α CTRW improved the AUC to 0.877. Conclusions The α CTRW could help discriminate the HER2-low-expressing and HER2-overexpressing BCs. Clinical relevance statement Human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC) might also benefit from the HER2-targeted therapy. Prediction of HER2-low-expressing BC or HER2-overexpressing BC is crucial for appropriate management. Advanced continuous-time random walk diffusion MRI offers a solution to this clinical issue. Key Points • Human epidermal receptor 2 (HER2)-low-expressing BC had lower α CTRW , D CTRW , β FROC , D FROC , μ FROC , α SEM , and DDC SEM values compared with HER2-overexpressing breast cancer. • The α CTRW was the single best diffusion metric (AUC = 0.802) for discrimination between the HER2-low-expressing and HER2-overexpressing breast canc